Lytix Biopharma As

Peptide Patents As

Amicoat As

Frederick Alan Leeson

John Sigurd Svendsen

Wenche Stensen

Øystein Rekdal

Oystein Rekdal

Stig Olov Magnus Engqvist

Trond Flægstad

Trond Flaegstad

Stig Olov Engqvist

ØYstein Rekdal

The present invention relates to a compound of formula (I) AA-AA-AA-R&#x2014;R(I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; Ris a N atom, which may be substituted by a branched or unbranched C-Calkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and Ris an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumour or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.

Antimicrobial compounds

The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R&#x2033;' but may not be a quaternary C atom; R&#x2032; is &#x2014;OR, &#x2014;CONH, &#x2014;CF, F, &#x2014;OH, &#x2014;NO, &#x2014;CN or &#x2014;OCORin which R, is Calkyl and each may be in the beta or gamma position; R&#x2033; is Calkyl or H; and R&#x2033;&#x2032; is H or a group consisting of 1-12 non-hydrogen atoms and may be linear, branched and/or incorporate one or more cyclic groups, cyclic groups may be aromatic and/or heterocyclic and 2 or more cyclic groups may be linked or fused and each may be substituted; or a salt, hydrate or solvate of a compound of formula (I) for use in the treatment or prevention of a neurodegenerative disorder by inhibiting formation of neurofibrillary (tau) tangles and/or by inhibiting Dyrk 1A. The invention further relates to non-therapeutic uses of these compounds. 

Neurodegenerative therapies

The present invention relates to a compound of formula (I) AA-AA-AA-R&#x2014;R(I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; Ris a N atom, which may be substituted by a branched or unbranched C-Calkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and Ris an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumor or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.

The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, &#x2014;b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.

Treatment of biofilms

Growing community of inventors

Tromso, Norway

Frederick Alan Leeson